The DOI matches its Crossref record; 5 of the 5 references it cites were found in a registry or an index.
Combining antibiotics with antivirulence compounds can have synergistic effects and reverse selection for antibiotic resistance in Pseudomonas aeruginosa
Published version of a preprint
Abstract
Antibiotics are losing efficacy due to the rapid evolution and spread of resistance. Treatments targeting bacterial virulence factors have been considered as alternatives because they target virulence instead of pathogen viability, and should therefore exert weaker selection for resistance than conventional antibiotics. However, antivirulence treatments rarely clear infections, which compromises their clinical applications. Here, we explore the potential of combining antivirulence drugs with antibiotics against the opportunistic human pathogen Pseudomonas aeruginosa. We combined two antivirulence compounds (gallium, a siderophore quencher, and furanone C-30, a quorum sensing [QS] inhibitor) together with four clinically relevant antibiotics (ciprofloxacin, colistin, meropenem, tobramycin) in 9×9 drug concentration matrices. We found that drug-interaction patterns were concentration dependent, with promising levels of synergies occurring at intermediate drug concentrations for certain drug pairs. We then tested whether antivirulence compounds are potent adjuvants, especially when treating antibiotic resistant (AtbR) clones. We found that the addition of antivirulence compounds to antibiotics could restore growth inhibition for most AtbR clones, and even abrogate or reverse selection for resistance in five drug combination cases. Molecular analyses suggest that selection against resistant clones occurs when resistance mechanisms involve restoration of protein synthesis, but not when efflux pumps are up-regulated. Altogether, our work provides a first systematic analysis of antivirulence-antibiotic combinatorial treatments and suggests that such combinations have the potential to be both effective in treating infections and in limiting the spread of antibiotic resistance.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
In the citing paper
“Iron-sequestering therapies such as gallium nitrate mimic iron to disrupt bacterial metabolism, effectively starving the pathogen163.”
From Pseudomonas aeruginosa: ecology, evolution, pathogenesis and antimicrobial susceptibility (2025) · cites this paper as [163]
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Tacconelli, E., Carrara, E., Savoldi, A., Harbarth, S., Mendelson, M., Monnet, D. L., Pulcini, C., Kahlmeter, G., Kluytmans, J., Carmeli, Y., et al. (2018) · The Lancet Infectious Diseases · doi:10.1016/s1473-3099(17)30753-3 · Cited by 6,142
Combination therapy in combating cancer
Mokhtari, R. B., Homayouni, T. S., Baluch, N., Morgatskaya, E., Kumar, S., Das, B., & Yeger, H. (2017) · Oncotarget · doi:10.18632/oncotarget.16723 · Cited by 2,543
Pseudomonas aeruginosa : new insights into pathogenesis and host defenses
Gellatly, S. L., & Hancock, R. E. W. (2013) · Pathogens and Disease · doi:10.1111/2049-632x.12033 · Cited by 1,295 · cited 1×
“aeruginosa is one of the ESKAPE pathogens with multidrug resistant strains spreading worldwide and infections becoming increasingly difficult to treat [19,20].”
BackgroundAntimicrobial Activity of Gallium Compounds on ESKAPE Pathogens
Hijazi, S., Visaggio, D., Pirolo, M., Frangipani, E., Bernstein, L., & Visca, P. (2018) · Frontiers in Cellular and Infection Microbiology · doi:10.3389/fcimb.2018.00316 · Cited by 144
Gallium-mediated siderophore quenching as an evolutionarily robust antibacterial treatment
Ross-Gillespie, A., Weigert, M., Brown, S. P., & Kümmerli, R. (2014) · Evolution, Medicine, and Public Health · doi:10.1093/emph/eou003 · Cited by 104 · cited 6×
“Specifically, gallium cannot be reduced and thereby irreversibly binds to siderophores and hinders siderophore-mediated iron uptake [25,27].”
BackgroundMethodInfluentialSelf-citation
Research works printed but not linked: 86
- GM Rossolini, 2014, Update on the antibiotic resistance crisis, Curr Opin Pharmacol, 18, 56, 10.1016/j.coph.2014.09.006 · DOI · Paper page
- World Health Organization (WHO), 2014, Antimicrobial resistance: Global Health Report on Surveillance, Bull World Health Organ
- J O’Neill, 2014, Antimicrobial Resistance: Tackling a crisis for the health and wealth of nations, Review on Antimicrobial Resistance
- R Laxminarayan, 2016, Access to effective antimicrobials: a worldwide challenge, Lancet, 387, 168, 10.1016/S0140-6736(15)00474-2 · DOI · Paper page
- SW Dickey, 2017, Different drugs for bad bugs: antivirulence strategies in the age of antibiotic resistance., Nat Rev Drug Discov, 16, 1, 10.1038/nrd.2017.23 · DOI · Paper page
- D Brown, 2015, Antibiotic resistance breakers: can repurposed drugs fill the antibiotic discovery void?, Nat Rev Drug Discov, 14, 821, 10.1038/nrd4675 · DOI · Paper page
- RC Allen, 2014, Targeting virulence: can we make evolution-proof drugs?, Nat Rev Microbiol, 12, 300, 10.1038/nrmicro3232 · DOI · Paper page
- PF Vale, 2014, Limiting Damage during Infection: Lessons from Infection Tolerance for Novel Therapeutics, PLoS Biol, 12, e1001769, 10.1371/journal.pbio.1001769 · DOI
- PF Vale, 2016, Beyond killing., Evol Med Public Heal, 2016, 148, 10.1093/emph/eow012 · DOI
- L Ternent, 2015, Bacterial fitness shapes the population dynamics of antibiotic-resistant and -susceptible bacteria in a model of combined antibiotic and anti-virulence treatment, J Theor Biol, 372, 1, 10.1016/j.jtbi.2015.02.011 · DOI
- M Hentzer, 2003, Attenuation of Pseudomonas aeruginosa virulence by quorum sensing inhibitors, EMBO J, 22, 3803, 10.1093/emboj/cdg366 · DOI · Paper page
- E Banin, 2008, The potential of desferrioxamine-gallium as an anti-Pseudomonas therapeutic agent, Proc Natl Acad Sci, 105, 16761, 10.1073/pnas.0808608105 · DOI · Paper page
- Z Zeng, 2008, Virtual screening for novel quorum sensing inhibitors to eradicate biofilm formation of Pseudomonas aeruginosa, Appl Microbiol Biotechnol, 79, 119, 10.1007/s00253-008-1406-5 · DOI · Paper page
- TH Jakobsen, 2012, Ajoene, a sulfur-rich molecule from garlic, inhibits genes controlled by quorum sensing, Antimicrob Agents Chemother, 56, 2314, 10.1128/AAC.05919-11 · DOI · Paper page
- G Michaud, 2016, Overcoming antibiotic resistance in Pseudomonas aeruginosa biofilms using glycopeptide dendrimers., Chem Sci, 7, 166, 10.1039/C5SC03635F · DOI
- CH Goss, 2018, Gallium disrupts bacterial iron metabolism and has therapeutic effects in mice and humans with lung infections, Sci Transl Med, 10, eaat7520, 10.1126/scitranslmed.aat7520 · DOI · Paper page
- DR Kirienko, 2019, Novel Pyoverdine Inhibitors Mitigate Pseudomonas aeruginosa Pathogenesis., Front Microbiol., 9, 3317, 10.3389/fmicb.2018.03317 · DOI
- EBM Breidenstein, 2011, Pseudomonas aeruginosa: all roads lead to resistance, Trends Microbiol, 19, 419, 10.1016/j.tim.2011.04.005 · DOI · Paper page
- C Rezzoagli, 2020, Harnessing bacterial interactions to manage infections: a review on the opportunistic pathogen Pseudomonas aeruginosa as a case example, J Med Microbiol, 69, 147, 10.1099/jmm.0.001134 · DOI
- M Hentzer, 2002, Inhibition of Quorum Sensing in Pseudomonas aeruginosa Biofilm Bacteria by a Halogenated Furanone Compound, Microbiology, 148, 87, 10.1099/00221287-148-1-87 · DOI · Paper page
- TB Rasmussen, 2005, Screening for Quorum-Sensing Inhibitors (QSI) by Use of a Novel Genetic System, the QSI Selector., J Bacteriol, 187, 1799, 10.1128/JB.187.5.1799-1814.2005 · DOI · Paper page
- T Defoirdt, 2018, Quorum-Sensing Systems as Targets for Antivirulence Therapy, Trends Microbiol, 26, 313, 10.1016/j.tim.2017.10.005 · DOI · Paper page
- Y Kaneko, 2007, The transition metal gallium disrupts Pseudomonas aeruginosa iron metabolism and has antimicrobial and antibiofilm activity, J Clin Invest, 117, 877, 10.1172/JCI30783 · DOI · Paper page
- DJ Smith, 2013, Targeting iron uptake to control Pseudomonas aeruginosa infections in cystic fibrosis, Eur Respir J, 42, 1723, 10.1183/09031936.00124012 · DOI
- F Imperi, 2013, Repurposing the antimycotic drug flucytosine for suppression of Pseudomonas aeruginosa pathogenicity, Proc Natl Acad Sci, 110, 7458, 10.1073/pnas.1222706110 · DOI
- K DeLeon, 2009, Gallium Maltolate Treatment Eradicates Pseudomonas aeruginosa Infection in Thermally Injured Mice, Antimicrob Agents Chemother, 53, 1331, 10.1128/AAC.01330-08 · DOI
- AB Kelson, 2013, Gallium-based anti-infectives: targeting microbial iron-uptake mechanisms, Curr Opin Pharmacol, 13, 707, 10.1016/j.coph.2013.07.001 · DOI · Paper page
- C Bonchi, 2014, Repurposing of gallium-based drugs for antibacterial therapy, BioFactors, 40, 303, 10.1002/biof.1159 · DOI
- S Hijazi, 2017, Gallium-Protoporphyrin IX Inhibits Pseudomonas aeruginosa Growth by Targeting Cytochromes, Front Cell Infect Microbiol, 7, 1, 10.3389/fcimb.2017.00012 · DOI
- AJ Manny, 1997, Reinvestigation of the sulfuric acid-catalysed cyclisation of brominated 2-alkyllevulinic acids to 3-alkyl-5-methylene-2(5H)-furanones., Tetrahedron, 53, 15813, 10.1016/S0040-4020(97)10034-5 · DOI
- M Manefield, 1999, Evidence that halogenated furanones from Delisea pulchra inhibit acylated homoserine lactone (AHL)-mediated gene expression by displacing the AHL signal from its receptor protein., Microbiology, 145, 283, 10.1099/13500872-145-2-283 · DOI · Paper page
- R Kümmerli, 2009, Phenotypic plasticity of a cooperative behaviour in bacteria, J Evol Biol, 22, 589, 10.1111/j.1420-9101.2008.01666.x · DOI · Paper page
- P Visca, 2007, Pyoverdine siderophores: from biogenesis to biosignificance, Trends Microbiol, 15, 22, 10.1016/j.tim.2006.11.004 · DOI · Paper page
- C Rezzoagli, 2018, Probing the evolutionary robustness of two repurposed drugs targeting iron uptake in Pseudomonas aeruginosa., Evol Med Public Heal, 1, 246
- M Bassetti, 2018, How to manage Pseudomonas aeruginosa infections., Drugs Context., 7, 212527, 10.7573/dic.212527 · DOI · Paper page
- A Rehman, 2019, Mechanisms of ciprofloxacin resistance in Pseudomonas aeruginosa: new approaches to an old problem, J Med Microbiol, 68, 1, 10.1099/jmm.0.000873 · DOI · Paper page
- K Poole, 2018, Expression of the multidrug resistance operon mexA-mexB-oprM in Pseudomonas aeruginosa: mexR encodes a regulator of operon expression, Antimicrob Agents Chemother, 40, 2021, 10.1128/AAC.40.9.2021 · DOI · Paper page
- N Jochumsen, 2016, The evolution of antimicrobial peptide resistance in Pseudomonas aeruginosa is shaped by strong epistatic interactions, Nat Commun, 7, 13002, 10.1038/ncomms13002 · DOI
- Y Tsutsumi, 2013, Identification of Novel Genes Responsible for Overexpression of ampC in Pseudomonas aeruginosa PAO1, Antimicrob Agents Chemother, 57, 5987, 10.1128/AAC.01291-13 · doi:10.1128/aac.01291-13
- C Muller, 2011, A Two-Component Regulatory System Interconnects Resistance to Polymyxins, Aminoglycosides, Fluoroquinolones, and beta-Lactams in Pseudomonas aeruginosa, Antimicrob Agents Chemother, 55, 1211, 10.1128/AAC.01252-10 · doi:10.1128/aac.01252-10
- L Zhang, 2008, Involvement of a novel efflux system in biofilm-specific resistance to antibiotics, J Bacteriol, 190, 4447, 10.1128/JB.01655-07 · DOI · Paper page
- J Quale, 2006, Interplay of efflux system, ampC, and oprD expression in carbapenem resistance of Pseudomonas aeruginosa clinical isolates, Antimicrob Agents Chemother, 50, 1633, 10.1128/AAC.50.5.1633-1641.2006 · DOI · Paper page
- Y ping Pan, 2016, Overexpression of MexAB-OprM efflux pump in carbapenem-resistant Pseudomonas aeruginosa., Arch Microbiol, 198, 565, 10.1007/s00203-016-1215-7 · DOI · Paper page
- A Bolard, 2017, Mutations in Gene fusA1 as a Novel Mechanism of Aminoglycoside Resistance in Clinical Strains of Pseudomonas aeruginosa, Antimicrob Agents Chemother, 62, e01835, 10.1128/AAC.01835-17 · DOI
- C López-Causapé, 2018, Evolution of the Pseudomonas aeruginosa Aminoglycoside Mutational Resistome In Vitro and in the Cystic Fibrosis Setting, Antimicrob Agents Chemother, 62, e02583, 10.1128/AAC.02583-17 · DOI
- K Poole, 2018, Expression of the multidrug resistance operon mexA-mexB-oprM in Pseudomonas aeruginosa: mexR encodes a regulator of operon expression, Antimicrob Agents Chemother, 40, 2021, 10.1128/AAC.40.9.2021 · DOI · Paper page
- PG Higgins, 2003, Mutations in GyrA, ParC, MexR and NfxB in clinical isolates of Pseudomonas aeruginosa., Int J Antimicrob Agents, 21, 409, 10.1016/S0924-8579(03)00009-8 · DOI
- AK Miller, 2011, PhoQ mutations promote lipid A modification and polymyxin resistance of Pseudomonas aeruginosa found in colistin-treated cystic fibrosis patients, Antimicrob Agents Chemother, 55, 5761, 10.1128/AAC.05391-11 · DOI · Paper page
- JY Lee, 2016, Evolved resistance to colistin and its loss due to genetic reversion in Pseudomonas aeruginosa., Sci Rep, 6, 25543, 10.1038/srep25543 · DOI
- K Barrow, 2009, Alterations in two-component regulatory systems of phoPQ and pmrAB are associated with polymyxin B resistance in clinical isolates of Pseudomonas aeruginosa, Antimicrob Agents Chemother, 53, 5150, 10.1128/AAC.00893-09 · DOI
- F Sanz-garcía, 2018, Mutation-Driven Evolution of Pseudomonas aeruginosa in the Presence of either Ceftazidime or Ceftazidime-Avibactam, Antimicrob Agents Chemother, 62, e01379, 10.1128/AAC.01379-18 · DOI
- GL Winsor, 2015, Enhanced annotations and features for comparing thousands of Pseudomonas genomes in the Pseudomonas genome database, Nucleic Acids Res, 44, D646, 10.1093/nar/gkv1227 · DOI · Paper page
- JF Acar, 2000, Antibiotic synergy and antagonism., Med Clin North Am, 84, 1391, 10.1016/S0025-7125(05)70294-7 · DOI
- J Lehár, 2009, Synergistic drug combinations tend to improve therapeutically relevant selectivity, Nat Biotechnol, 27, 659, 10.1038/nbt.1549 · DOI · Paper page
- MA Alkawash, 2006, Alginate lyase enhances antibiotic killing of mucoid Pseudomonas aeruginosa in biofilms, Apmis, 114, 131, 10.1111/j.1600-0463.2006.apm_356.x · DOI · Paper page
- J Luo, 2017, Baicalin inhibits biofilm formation, attenuates the quorum sensing-controlled virulence and enhances Pseudomonas aeruginosa clearance in a mouse peritoneal implant infection model., PLoS ONE., 12, e0176883, 10.1371/journal.pone.0176883 · DOI · Paper page
- J Turnidge, 2007, Setting and revising antibacterial susceptibility breakpoints, Clin Microbiol Rev, 20, 391, 10.1128/CMR.00047-06 · DOI · Paper page
- HS Sader, 2017, Pseudomonas aeruginosa Antimicrobial Susceptibility Results from Four Years (2012 to 2015) of the International Network for Optimal Resistance Monitoring Program in the United States., Antimicrob Agents Chemother, 61, e02252, 10.1128/AAC.02252-16 · DOI
- R Chait, 2007, Antibiotic interactions that select against resistance, Nature, 446, 668, 10.1038/nature05685 · DOI · Paper page
- M Hegreness, 2008, Accelerated evolution of resistance in multidrug environments, Proc Natl Acad Sci, 105, 13977, 10.1073/pnas.0805965105 · DOI · Paper page
- M Baym, 2016, Multidrug evolutionary strategies to reverse antibiotic resistance, Science, 351, aad3292, 10.1126/science.aad3292 · DOI · Paper page
- T Maeda, 2012, Quorum quenching quandary: resistance to antivirulence compounds., ISME J, 6, 493, 10.1038/ismej.2011.122 · DOI · Paper page
- N Wale, 2017, Resource limitation prevents the emergence of drug resistance by intensifying within-host competition, Proc Natl Acad Sci, 114, 13774, 10.1073/pnas.1715874115 · DOI
- B Mellbye, 2011, The sociomicrobiology of antivirulence drug resistance: a proof of concept., MBio, 2, e00131, 10.1128/mBio.00131-11 · DOI · Paper page
- JP Gerdt, 2014, Competition Studies Confirm Two Major Barriers That Can Preclude the Spread of Resistance to Quorum-Sensing Inhibitors in Bacteria., ACS Chem Biol, 9, 2291, 10.1021/cb5004288 · DOI
- NM Vega, 2014, Collective antibiotic resistance: Mechanisms and implications, Curr Opin Microbiol, 21, 28, 10.1016/j.mib.2014.09.003 · DOI · Paper page
- MA Fischbach, 2011, Combination therapies for combating antimicrobial resistance, Curr Opin Microbiol, 14, 519, 10.1016/j.mib.2011.08.003 · DOI · Paper page
- LL Silver, 2011, Challenges of Antibacterial Discovery., Clin Microbiol Rev, 24, 71, 10.1128/CMR.00030-10 · DOI · Paper page
- B Tepekule, 2017, Modeling antibiotic treatment in hospitals: A systematic approach shows benefits of combination therapy over cycling, mixing, and mono-drug therapies., PLoS Comput Biol., 13, e1005745, 10.1371/journal.pcbi.1005745 · DOI
- M Tyers, 2019, Drug combinations: a strategy to extend the life of antibiotics in the 21st century, Nat Rev Microbiol, 17, 141, 10.1038/s41579-018-0141-x · DOI · Paper page
- T Cihlar, 2016, Current status and prospects of HIV treatment., Curr Opin Virol, 18, 50, 10.1016/j.coviro.2016.03.004 · DOI · Paper page
- AM Ginsberg, 2007, Challenges in tuberculosis drug research and development, Nat Med, 13, 290, 10.1038/nm0307-290 · DOI · Paper page
- L Zhou, 2014, The Social Biology of Quorum Sensing in a Naturalistic Host Pathogen System, Curr Biol, 24, 2417, 10.1016/j.cub.2014.08.049 · DOI
- C Rezzoagli, 2019, In vivo microscopy reveals the impact of Pseudomonas aeruginosa social interactions on host colonization, ISME J, 13, 2403, 10.1038/s41396-019-0442-8 · DOI
- CR Proctor, 2020, Furanone quorum-sensing inhibitors with potential as novel therapeutics against Pseudomonas aeruginosa, J Med Microbiol, 69, 195, 10.1099/jmm.0.001144 · DOI
- K-H Choi, 2006, mini-Tn7 insertion in bacteria with single attTn7 sites: example Pseudomonas aeruginosa, Nat Protoc, 1, 153, 10.1038/nprot.2006.24 · DOI · Paper page
- Ö Özkaya, 2018, Cheating on Cheaters Stabilizes Cooperation in Pseudomonas aeruginosa, Curr Biol, 26, 2070, 10.1016/j.cub.2018.04.093 · DOI
- PS Ocampo, 2014, Antagonism between bacteriostatic and bactericidal antibiotics is prevalent, Antimicrob Agents Chemother, 58, 4573, 10.1128/AAC.02463-14 · DOI · Paper page
- JR Morones-Ramirez, 2013, Silver Enhances Antibiotic Activity Against Gram-Negative Bacteria., Sci Transl Med., 5, 190ra81, 10.1126/scitranslmed.3006276 · DOI · Paper page
- DY Baeder, 2016, Antimicrobial combinations: Bliss independence and Loewe additivity derived from mechanistic multi-hit models., Philos Trans R Soc B Biol Sci, 371, 20150294, 10.1098/rstb.2015.0294 · DOI
- C Barbosa, 2018, Antibiotic combination efficacy (ACE) networks for a Pseudomonas aeruginosa model., PLoS Biol, 16, e2004356, 10.1371/journal.pbio.2004356 · DOI
- AM Bolger, 2014, Trimmomatic: a flexible trimmer for Illumina sequence data, Bioinformatics, 30, 2114, 10.1093/bioinformatics/btu170 · DOI · Paper page
- P Danecek, 2011, The variant call format and VCFtools, Bioinformatics, 27, 2156, 10.1093/bioinformatics/btr330 · DOI · Paper page
- A Ross-Gillespie, 2007, Frequency dependence and cooperation: theory and a test with bacteria, Am Nat, 170, 331, 10.1086/519860 · DOI · Paper page
- R Development Core Team, 2013, R: A language and environment for statistical computing.
- C Ritz, 2015, Dose-Response Analysis Using R., PLoS ONE., 10, e0146021, 10.1371/journal.pone.0146021 · DOI · Paper page
Cited by
Towards the sustainable discovery and development of new antibiotics
Miethke, M., Pieroni, M., Weber, T., Brönstrup, M., Hammann, P., Halby, L., Arimondo, P. B., Glaser, P., Aigle, B., Bode, H. B., et al. (2021) · Nature Reviews Chemistry · doi:10.1038/s41570-021-00313-1 · Cited by 1,151
Liao, C., Huang, X., Wang, Q., Yao, D., & Lu, W. (2022) · Frontiers in Cellular and Infection Microbiology · doi:10.3389/fcimb.2022.926758 · Cited by 309
Pseudomonas aeruginosa: ecology, evolution, pathogenesis and antimicrobial susceptibility
Letizia, M., Diggle, S. P., & Whiteley, M. (2025) · Nature Reviews Microbiology · doi:10.1038/s41579-025-01193-8 · Cited by 231
Antimicrobial activity of iron-depriving pyoverdines against human opportunistic pathogens
Vollenweider, V., Rehm, K., Chepkirui, C., Pérez-Berlanga, M., Polymenidou, M., Piel, J., Bigler, L., & Kümmerli, R. (2024) · eLife · doi:10.7554/elife.92493.3 · Cited by 3
Self-citation
Metadata
- Authors
- Rezzoagli, C., Archetti, M., Mignot, I., Baumgartner, M., & Kümmerli, R.
- Venue
- PLOS Biology
- Publisher
- Public Library of Science (PLoS)
- Published
- 2020-08-18
- Volume
- 18
- Issue
- 8
- Pages
- e3000805
- ISSN
- 1545-7885
- Cited by
- 126
- References
- 5
- Language
- en
- Funders
- H2020 European Research Council (681295)
- Schweizerischer Nationalfonds zur Förderung der Wissenschaftlichen Forschung (31003A_182499)
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.